Methotrexate as a game-changer for COVID-19 vaccine-related dermal nodules

During the COVID-19 pandemic, an unexpected issue emerged among patients who had previously received cosmetic dermal fillers. Reports surfaced of delayed-onset swelling, nodules, and other inflammatory reactions following mRNA-based vaccines like Moderna and P zer and the viral vector AstraZeneca vaccine. Although rare, these side effects raised concerns within the medical and cosmetic industries. Initially, the complications were thought to result from a Type IV hypersensitivity reaction, an immune system response to what it recognized as foreign material, such as fillers [1]. While treatments such as antihistamines, hyaluronidase, and intralesional steroids were attempted, many patients experienced only limited or temporary relief. Some presented with severe cases, including clusters of multiple hard nodules in areas treated with llers, causing significant cosmetic and psychological distress [2]. These challenges have le healthcare providers and dermatologists questioning: How should these vaccine-associated filler reactions be managed effectively? Are current treatment protocols enough to address these complications?